Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended schedule, escalated dose temozolomide versus dacarbazine in metastatic melanoma
2004-000654-23Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2004
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of temozolomide in melanoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Nov 2004; status: completed.
02
Drugs
temozolomide
03
Conditions
melanoma
Beyond the preview
Go deeper on 2004-000654-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000654-23.